Titan pharmaceuticals inc (TTNP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-16,458

-9,023

-14,307

5,135

-11,279

-2,403

9,711

-15,180

-15,203

-6,834

-5,886

Adjustments to reconcile loss to net cash used in operating activities:
Non-cash gain on inventory received from termination of license agreement

0

1,293

0

0

-

-

-

-

-

-

-

Depreciation and amortization

244

380

417

377

358

353

107

17

32

85

169

Non-cash interest expense

613

490

141

0

0

-

-

-

-

-

-

Non-cash gain on termination of royalty purchase agreement

-

-

-

-

-

-

8,962

0

0

-

-

Amortization of discount on long-term debt

-

-

-

-

-

-

-

-

1,520

132

-

Interest on royalty liability

-

-

-

-

-

-

-

-347

1,309

0

-

Non-cash loss on changes in fair value of warrants

-1,110

0

-

-

-

-

-1,737

1,766

-

-

-

Non-cash gain on debt extinguishment

226

0

619

825

-4,512

1,083

1,860

0

0

-

-

Non-cash gain on changes in fair value of derivatives

-

-

0

0

-

-

-

-

-

-

-

Non-cash (gain) loss on changes in fair value of warrants

-

-

-

-

-

-

-

-

1,862

0

-

Gain on investments

-

-

-

-

-

-

-

-

-

-

9

Gain on disposition of property and equipment

-

-

-

-

-

-

-

-

-

-

-3

Stock-based compensation

572

1,557

1,687

1,039

1,026

543

678

2,581

1,177

733

1,523

Changes in operating assets and liabilities:
Receivables

-744

1,672

-3,522

-626

245

-850

172

926

2,495

1,159

-

Inventory

-264

-31

0

0

-

-

-

-

-

-

-

Contract assets

-99

-120

0

0

-

-

-

-

-

-

-

Prepaid expenses and other assets

547

185

125

63

29

-59

-483

-149

542

44

-405

Accounts payable

-125

542

-2,194

-1,143

-250

-710

1,351

-1,022

2,332

2,122

-158

Accrued sales allowances

809

0

-

-

-

-

-

-

-

-

-

Other accrued liabilities

30

443

-1,199

1,147

112

172

-340

417

-744

308

-1,454

Deferred revenue

-313

313

0

0

-

-

-

-

-

-

-

Other

41

134

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-1,671

-3,646

-9,058

14,375

0

0

-

Net cash provided by (used in) operating activities

-

-

-

-

-

-5,865

-9,799

1,830

-14,476

-

-

Net cash used in operating activities

-15,445

-8,431

-12,677

6,293

-7,466

-

-

-

-

-4,657

-5,407

Cash flows from investing activities:
Purchases of property and equipment

256

416

175

171

133

18

318

1,154

236

28

7

Disposals of furniture and equipment

-

-

-

-

-

-

-

-

2

0

-

Net cash used in investing activities

-

-

-

-

-

-18

-318

-1,154

-234

-

-

Proceeds from the sale of investments

-

-

-

-

-

-

-

-

-

-

9

Net cash used in investing activities

-256

-416

-175

-171

-133

-

-

-

-

-28

2

Cash flows from financing activities:
Proceeds from equity offerings

9,665

9,651

-

-

-

-

-

-

-

-

-

Sale of common & preferred stock

-

-

0

0

-

-

-

-

-

-

-

Issuance of warrants

0

51

0

0

-

-

-

-

-

-

-

Proceeds from issuance of common stock from the exercise of stock options

-

-

0

27

0

0

113

0

0

0

555

Proceeds from issuance of common stock and warrants, net of issuance costs

-

-

-

-

-

9,591

4,925

7,516

0

0

478

Issuance of common stock from the vesting of restricted shares

-

-

-

-

14

36

0

0

-

-

-

Net proceeds from the exercises of common stock warrants

1,603

3,268

0

0

-

-

1,275

4,897

0

-

-

Proceeds from the issuance of debt

0

650

6,729

0

0

-

-

-

-

-

-

Proceeds from royalty financing

-

-

-

-

-

-

-

-

8,000

0

-

Proceeds from long-term debt

-

-

-

-

-

-

-

-

16,500

5,000

3,000

Payments of long-term debt

0

3,000

0

0

-

-

2,500

393

7,564

435

-

Net cash provided by (used in) financing activities

-

-

-

-

-

9,555

3,813

12,020

16,936

-

-

Net cash provided by financing activities

11,268

10,620

6,729

27

-14

-

-

-

-

4,565

4,033

Net decrease in cash and cash equivalents

-4,433

1,773

-6,123

6,149

-7,613

3,672

-6,304

12,696

2,226

-120

-1,372

Supplemental disclosure of cash flow information:
Interest paid

432

471

298

0

0

-

-

-

-

-

-

Warrants issued

0

6,348

287

0

-

-

-

-

-

-

-

Derivatives issued

0

159

0

0

-

-

-

-

-

-

-

Deemed dividend on trigger of down round provision

0

285

0

0

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable

11

163

0

0

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

1,568

2,576

1,652

678

9

Schedule of non-cash transactions
Settlement of long-term debt

-

-

-

-

-

-

7,500

0

0

-

-

Fair value of warrants at the time of exercise

-

-

-

-

-

-

4,686

0

0

-

-

Fair value of warrants at the time of reclassification to equity

-

-

-

-

8,646

-

0

-

-

-

-

Retirement of preferred stock upon dissolution of Ingenex, Inc.

-

-

-

-

-

-

-

-

-

1,241

-